Gilead Prevails in HIV Antitrust Trial

Foster City, Calif., June 30, 2023 – Gilead Sciences, Inc. announced today that a jury in the U.S. District Court for the Northern District of California returned a verdict in favor of Gilead in the HIV antitrust trial. The verdict affirms that a 2014 patent settlement between Gilead and Teva did not violate antitrust law and was not a reverse payment. On the contrary, it promoted competition and enabled individuals to obtain generic versions of Atripla® and Truvada® before the expiration of Gilead’s patents protecting those medicines. 

“Gilead is committed to enabling broad access to our potentially life-saving HIV medications, and the verdict confirms that our 2014 patent settlement between Gilead and Teva did not violate antitrust law,” said Deborah Telman, Executive Vice President, Corporate Affairs and General Counsel, Gilead Sciences. “With this matter now behind us, we will continue to focus on pursuing innovation to address the unmet needs of people affected by HIV around the world and we remain committed to our shared goal to end the HIV epidemic for everyone, everywhere. We thank the jury for their time and careful attention to the complex issues in this case.

Patents are critical to innovation and promote progress. Gilead is heavily invested in research and development that has resulted in scientific innovation which helped change the trajectory of the HIV epidemic – from Gilead’s first HIV medicine, which the FDA approved in 2001, to the continued development of new options and pioneering of single tablet regimens for the treatment and prevention of HIV.

About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company’s website at, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.